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ABSTRACT
The taxanes are effective microtubule-stabilizing chemotherapy drugs that inhibit 
mitosis, induce apoptosis, and produce regression in a fraction of cancers that arise at 
many sites including the ovary. Novel therapeutic targets that augment taxane effects 
are needed to improve clinical chemotherapy response in CCNE1-amplified high grade 
serous ovarian cancer (HGSOC) cells. In this study, we conducted an siRNA-based 
kinome screen to identify modulators of mitotic progression in CCNE1-amplified HGSOC 
cells that may influence clinical paclitaxel response. PLK1 is overexpressed in many 
types of cancer, which correlates with poor prognosis. Here, we identified a novel 
synthetic lethal interaction of the clinical PLK1 inhibitor BI6727 and the microtubule-
targeting drug paclitaxel in HGSOC cell lines with CCNE1-amplification and elucidated 
the underlying molecular mechanisms of this synergism. BI6727 synergistically induces 
apoptosis together with paclitaxel in different cell lines including a patient-derived 
primary ovarian cancer culture. Moreover, the inhibition of PLK1 reduced the paclitaxel-
induced neurotoxicity in a neurite outgrowth assay. Mechanistically, the combinatorial 
treatment with BI6727/paclitaxel triggers mitotic arrest, which initiates mitochondrial 
apoptosis by inactivation of anti-apoptotic BCL-2 family proteins, followed by significant 
loss of the mitochondrial membrane potential and activation of caspase-dependent 
effector pathways. This conclusion is supported by data showing that BI6727/
paclitaxel-co-treatment stabilizes FBW7, a component of SCF-type ubiquitin ligases 
that bind and regulate key modulators of cell division and growth including MCL-1 
and Cyclin E. This identification of a novel synthetic lethality of PLK1 inhibitors and a 
microtubule-stabilizing drug has important implications for developing PLK1 inhibitor-
based combination treatments in CCNE1-amplified HGSOC cells.
INTRODUCTION
High grade serous ovarian cancer (HGSOC) 
accounts for 70-80% of ovarian cancer-related deaths. 
Despite major improvements in the understanding of 
ovarian cancer carcinogenesis, most patients relapse after 
primary treatment and succumb to disease progression. 
In a recent study a total of 16,854 patients with HGSOC 
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were analyzed. Median overall survival was 40.7 months 
among high grade patients [1]. Chemotherapy remains 
the principal form of adjuvant and neoadjuvant treatment 
for HGSOC. A significant advance in chemotherapeutic 
management was the introduction of paclitaxel to the 
treatment of HGSOC patients in which the combination 
of cisplatin and paclitaxel conferred a substantial survival 
advantage over cisplatin and cyclophosphamide. The 
toxicity profile favoring the carboplatin/paclitaxel regimen 
has now established this as standard of care in the first-line 
setting. Although changes to both chemotherapy schedules 
and routes of administration are associated with improved 
survival, it appears that a therapeutic ceiling with these 
drugs has been reached. Despite a good chemosensitivity 
of HGSOC, a significant frequency of these patients fails 
to respond to the primary treatment with taxanes. In recent 
years, inhibitors of poly(ADP-ribose) polymerase (PARP) 
have emerged as one of the most exciting new therapies 
for the treatment of HGSOC, based on the vulnerability 
of ovarian cancer cells to agents that interrupt DNA repair 
[2]. Bevacizumab, a humanized monoclonal antibody 
targeting vascular endothelial growth factor, showing 
improvement in progression-free survival in combination 
with standard chemotherapy has enriched the modern 
armament targeting HGSOC [3].
While mutations in oncogenes or tumor suppressor 
genes are relatively seldom in HGSOC except in genes 
coding for TP53, BRCA1 and BRCA2, primary ovarian 
cancer tissues exhibit a high frequency of genomic 
structural variations, including multiple gains and losses 
of genomic DNA making this cancer type an example 
of chromosomal instability [4, 5]. Structural genomic 
variations are a frequent mechanism for the functional 
knockout of tumor suppressors in HGSOC, including 
RB1 and NF1 [6]. Mutations in BRCA1 and BRCA2 and, 
less frequent in other components of the homologous 
recombination (HR) pathway are the origin for defects in 
HR DNA repair pathway in approximately 50% HGSOC. 
The signaling pathways of the half of HGSOC that do not 
exhibit functional defects in HR remain to be elucidated. 
Approximately 30% of this subclass were found to have 
amplifications of the CCNE1 gene, which codes for the 
G1/S-specific Cyclin E1, and this is likely an early event 
in the development of HGSOC [5].
Polo-like kinase 1 (PLK1) controls multiple phases 
of the cell-cycle progression [7, 8]. While the expression 
of PLK1 is below the limit of detection in normal 
tissues like heart, kidney, liver, brain, lung and pancreas, 
proliferating tissues like placenta, testis and bone marrow 
show high levels of PLK1 transcripts and protein [9, 
10]. Early observations that linked PLK1 expression 
with cancer were from studies showing increased PLK1 
expression in primary neoplastic tissues [9, 11]. PLK1 was 
shown to be overexpressed in a large spectrum of cancer 
types, including non-small cell lung cancer (NSCLC) [12], 
breast [13] ovarian [14] and head and neck squamous 
carcinomas [15] and melanoma [16]. Remarkably, high 
levels of PLK1 have been correlated with poor patient 
prognosis in different types of cancer including NSCLC 
[12], colon cancer [17] and hepatoblastoma [18]. 
Interestingly, a high risk of metastases has been associated 
with high PLK1 levels, implying a role for PLK1 in 
more aggressive tumors and the potential of PLK1 as a 
prognostic marker. The validation of PLK1 in multiple 
animal models revealed PLK1 as an important cancer 
target [19–22]. These observations prompted an intense 
search of the pharmaceutical industry for small molecule 
inhibitors of PLK1. The most advances PLK1 inhibitor in 
the clinic, Volasertib (BI6727) in combination with low 
dose cytarabine has received a Breakthrough Therapy 
designation from the FDA for its potential as a treatment 
for patients with untreated acute myeloid leukemia who 
are ineligible for intensive remission induction therapy 
[23]. In a study on normal ovaries (n=9), cystadenomas 
(n=17), borderline tumors (n=13) and ovarian carcinomas 
(n=77), the frequency of PLK1 expression was low in 
normal epithelium and borderline tumors, but in ovarian 
carcinomas 26% of the cancer tissues were PLK1-positive 
[14]. In ovarian cancer, a significant correlation between 
PLK1-positive cells and the histological grade was found 
[24]. The number of PLK1-positive cells was significantly 
higher in ovarian cancers designated as grade 3 than in 
cancers designated as grade 1 (P<0.001). Recently, in 
patients with ovarian cancer, comparable antitumor 
activity was observed between Volasertib treatment and 
the investigator’s choice of single agent chemotherapy, 
including microtubule-targeting agents [25] suggesting 
that PLK1 could be considered as an attractive target 
for approaches aiming at the identification of synthetic 
lethality in the treatment of HGSOC.
The exploration of synergistic strategies that help 
to lower clinically relevant doses and to improve the 
response to taxane-based chemotherapy in HGSOC 
patients with amplification of CCNE1 is a key aspect of 
our investigation. In this study, we performed an siRNA-
based kinome screen in the OVCAR-3 cell line to identify 
regulators of mitotic progression and cell death that could 
augment the effect of taxanes such as paclitaxel.
RESULTS
A kinome-wide siRNA screen identifies 
modulators of cell growth and apoptosis in 
ovarian cancer cells with CCNE1-amplification
At first, we screened the Cyclin E expression of 
a small panel of ovarian cancer cells (Supplementary 
Figure 1) whose genotypes were analyzed recently [26]. 
For the subsequent analysis we selected an ovarian cancer 
cell line with CCNE1-amplification like OVCAR-3 cells 
exhibiting strong Cyclin E expression and a reasonable 
doubling time, which is an important prerequisite for a 
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successful siRNA screening. We used a multi-step strategy 
to identify novel therapeutic targets in ovarian cancer cells 
that induce cell death and might improve taxane-based 
effects: (1) screening of 711 pools of siRNAs (Dharmacon 
kinome library) targeting individual human kinases; (2) 
specific hits were validated using single siRNAs (cherry 
picking) that made up the pool in the primary screening; 
and (3) assays for cell viability, cell death (Caspase-3/7 
activity, Annexin staining) and cell cycle distribution 
(FACS measurements) of siRNA-treated OVCAR-3 
cells (Supplementary Figure 2A). This cell line has high-
level CCNE1-amplification and expression confirming 
previous data [27]. Our study was conducted to identify 
potent regulators of cell growth and apoptosis that were 
subsequently tested for their capability to synergize with 
paclitaxel.
In the primary screen of ovarian cancer cells 
with CCNE1-amplification, 48 h after transfection of 
the Dharmacon kinome library we first monitored cell 
viability and Caspase-3/7 activities of OVCAR-3 cells 
in a multiplexed assay (Supplementary Figure 2A-2C). 
As an additional test for apoptosis, 48 h after siRNA-
transfection OVCAR-3 cells were stained for Annexin 
V (PE-Annexin V/7-AAD) and monitored by flow 
cytometry (Supplementary Figure 2A, 2D). For all three 
experiments, we determined the Top-20 list of targets 
whose depletion induced the most pronounced response 
on the growth and viability of cells (Supplementary 
Figure 2B-2D). We determined a high correlation between 
both apoptosis assays across triplicate plates (median 
correlation coefficient = 0.7) and a mean coefficient of 
repeatability for all genes tested of 0.1, indicating the high 
reproducibility of our screenings. Among the identified 
hits, the inhibition of Polo-like kinase 1 (PLK1), which 
is a key regulator of the progression through mitosis in 
mammalian cells [7, 28–29], was selected for further 
analysis based on its Top-20 ranking in all three assays 
with a particular focus on its highest potential to induce 
apoptosis in OVCAR-3 cells as determined by Annexin V 
staining (Supplementary Figure 2D).
Several studies have demonstrated that siRNAs 
are not always specific and can have off-target effects. 
To exclude off-target effects, we tested all 4 siRNA that 
were components of the pool used for the primary screen. 
All 4 siRNAs resulted in a pronounced downregulation of 
the protein level and a significant increase in Annexin V 
staining (Supplementary Figure 2E).
Genomic profiling of paclitaxel-treated 
OVCAR-3 cells
We compared the microarray expression profiles of 
OVCAR-3 cells treated with low doses paclitaxel for 24 h 
with OVCAR-3 cells cultured in normal medium in order 
to identify kinase genes that are differentially expressed by 
using the Illumina HumanHT-12 v4 Expression BeadChip 
and to find out whether PLK1 might be a realistic target 
in paclitaxel-treated OVCAR-3 cells (Supplementary 
Figure 3A). To identify protein kinases that could act 
in concert with paclitaxel for the induction of synthetic 
lethality, we used for the microarray expression profiling 
sub-lethal doses of paclitaxel. At a concentration of 3.5 
nM, the analysis of the microarray expression profile 
revealed an upregulation of classical regulators of G2/M 
like Aurora A, PLK4 and PLK1 compared to the DMSO 
control (Supplementary Figure 3A, Supplementary Table 
1). Additional cell cycle regulators were also altered, 
including up-regulated CDK6, which has been previously 
described based on its aberrant expression and association 
with paclitaxel-based therapy in ovarian cancer patients 
[30, 31] and also including CDK7, which regulates the 
assembly of the CDK1/Cyclin B1 complex [32, 33]. 
These transcriptional alterations reflect the upregulation 
of mitotic regulators including PLK1 and stress response 
genes upon treatment of OVCAR-3 cells with low doses 
of paclitaxel. To analyze in more detail whether PLK1 
could be an attractive target for a combinatorial approach 
with paclitaxel, we treated OVCAR-3 cells with increasing 
concentrations of paclitaxel for 24 h and observed 
escalating levels of PLK1 expression (10 nM: 140%) 
(Supplementary Figure 3B, upper panel) associated with 
an enrichment of cells in G2/M (Supplementary Figure 3B, 
lower panel).
Various lines of evidence suggest that cells held in 
mitosis for a prolonged period, for instance by microtubule 
targeting agents like paclitaxel, can undergo different fates 
including death by apoptosis [34]. Prolonged mitotic arrest 
is a key determinant of cell death with or without taxane 
treatment [35–37]. The treatment of OVCAR-3 cells with 
paclitaxel can not only prolong the duration of mitosis 
and thereby increase the percentage of apoptotic cells, it 
also increases the expression of PLK1 (Supplementary 
Figure 3A, 3B, upper panel), which is an attractive target 
in OVCAR-3 cells based on our kinome-wide siRNA 
screen (Supplementary Figure 2). Considering both 
aspects, we tested the combinatorial inhibition of PLK1 
and the microtubule dynamics by paclitaxel in ovarian 
cancer cells with CCNE1-amplification.
Small molecule inhibitors of PLK1 decrease the 
viability of ovarian cancer cells with CCNE1-
amplification and sensitize cells to paclitaxel
Although the inhibition of PLK1 functions by small-
molecule inhibitors of its catalytic activity/subcellular 
localization or by RNAi-mediated depletion revealed that 
differential levels of PLK1 are required for the viability 
of cancer vs. normal cells [10, 38–42], the effect of PLK1 
inhibition in HGSOC cells with CCNE1-amplification 
remains elusive. To study this aspect, at first the viability 
of OVCAR-3 cells following the treatment with the 
potent PLK inhibitor BI6727 [39] for 24 h, 48 h, and 72 
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h was determined. While BI6727 at low concentrations 
(≤10 nM) induced only a subtle effect in OVCAR-3 cells 
after 72 h of incubation, cell viability was significantly 
reduced to 26% at a dose of 50 nM (P < 0.01) and to 11% 
at 75 nM compared with DMSO-treated cells (P < 0.01; 
Figure 1A). After 96 h, more pronounced effects were 
observed: 65% at 25 nM, 11% at 50 nM and 10% at 75 
nM (P < 0.01). While the treatment with paclitaxel for 
72 h at concentrations ≤ 2 nM had only a small effect 
on the viability of OVCAR-3 cells, the treatment with 5 
nM paclitaxel induced a significant reduction to 60% (P 
< 0.001) and to 13% at 10 nM compared with DMSO-
treated cells (P < 0.001; Figure 1B). To evaluate whether 
these effects are cell-type specific, we treated a second 
cell line with CCNE1-amplification, COV318 cells, 
with increasing BI6727 concentrations. Due to the low 
proliferative activity of COV318 cells, we extended the 
observation period for our assays. Whereas BI6727 at 
low concentrations (≤10 nM) induced only a small effect 
in COV318 cells after 96 h of incubation, cell viability 
was significantly reduced to 48% at a dose of 50 nM (P 
< 0.001) and to 50% at 75 nM compared with DMSO-
treated cells (P < 0.01; Supplementary Figure 4A). After 
168 h more intense effects were measured: 47% at 25 
nM, 37% at 50 nM and to 35% at 75 nM (P < 0.01). The 
treatment with 30 nM paclitaxel alone for 144 h reduced 
cellular viability to 24% (P < 0.05) and for 168 h to 18% 
(P < 0.01) compared with control cells (Supplementary 
Figure 4B).
The cell cycle analysis by FACS revealed that 
a treatment with 20 nM BI6727 for 24 h increases the 
fraction of OVCAR-3 cells in the G2/M phase from 34% 
to 44% (P < 0.01) (Figure 1C, left panel) due to prolonged 
mitotic arrest as evidenced by microscopical inspection. 
The treatment with increasing concentrations of paclitaxel 
(2-4 nM) led to a minor increase of OVCAR-3 cells in the 
G2/M phase from 32% to 38%. To further evaluate whether 
the cells are arrested in mitosis, we used phospho-histone 
H3 (pH3) as mitotic marker. The assessment by western 
blotting and FACS-based measurements revealed that 
cells that were treated with either agent alone showed only 
an increase of the pH3 signal for 20 nM BI6727 (Figure 
1C, upper and lower right panels). The levels of mitotic 
markers like Cyclin B1, PLK1 and phospho-Aurora B 
remained nearly unchanged upon single agent-treatment. 
In contrast to the single treatments, the combination of 
20 nM BI6727 with 2-4 nM paclitaxel induced a visible 
increase in the levels of the mitotic markers Cyclin B1, 
PLK1 and phospho-Aurora B (Figure 1C, upper right 
panel). Remarkably, the combinatorial treatment (24 h) of 
3.5 nM paclitaxel and 20 nM BI6727 induced a strong 
increase to 61% of OVCAR-3 cells in the G2/M phase 
(Figure 1C, left panel, P < 0.01) and to 33% by FACS-
based determination of pH3-positive cells (Figure 1C, 
lower right panel).
To follow up upon this pronounced combinatorial 
effect, we tested the viability of HGSOC cells following 
single or combinatorial treatments. We analyzed the 
effect of 20 nM BI6727 together with paclitaxel in 
concentrations from 2-4 nM on the viability of OVCAR-3 
cells for 24-96 h (Figure 1D-1G). BI6727 alone at 20 nM 
affected the viability of OVCAR-3 cells compared with 
controls (24 h, 112%, 48 h, 105%, 72h, 101%; 96 h, 76%) 
(Figure 1D-1G). For comparison, after a treatment for 96 
h paclitaxel alone at concentrations between 2 and 4 nM 
reduced cell viability to 86% (2 nM) or 57% (4 nM) (P 
< 0.05) (Figure 1G). Interestingly, together with 20 nM 
BI6727, 2 nM paclitaxel reduced cell proliferation to 50% 
(P < 0.05), with 2.5 nM to 40% (P < 0.05), with 3 nM to 
28% (P < 0.05), with 3.5 nM to 20% (P < 0.01) and with 
4 nM to 16% (P < 0.001) (Figure 1F). The combination 
of 4 nM paclitaxel and 20 nM BI6727 for 96 h revealed a 
very pronounced effect with a residual viability of 12% (P 
< 0.001) (Figure 1G). The treatment of OVCAR-3 cells 
with BI6727 decreased the dose of paclitaxel required to 
reduce cancer cell growth by 50% (GI50) by 2.8–3.0-fold. 
Therefore, the application of the PLK1 inhibitor BI6727 
sensitized ovarian cancer cells to paclitaxel in a synergistic 
manner (combination index <1).
Moreover, COV318 cells were subjected to a 
combinatorial treatment with 20 nM BI6727. Interestingly, 
together with 20 nM BI6727, 1 nM paclitaxel reduced 
cell proliferation after 120 h to 67% (compared to 97%, 
1 nM paclitaxel alone), with 2 nM to 52% (P < 0.05) 
(compared to 93%, 2 nM paclitaxel alone), and with 5 nM 
to 47% (P < 0.01) (compared to 80%, 5 nM paclitaxel 
alone), (Supplementary Figure 4C). After 144 h the 
combinatorial incubation with 20 nM BI6727 and 5 nM 
paclitaxel reduced cell proliferation to 43% (P < 0.05) 
(Supplementary Figure 4D). The treatment of COV318 
cells with BI6727 decreased the dose of paclitaxel 
required to reduce cancer cell growth by 50% (GI50) 
from 25 nM to 2 nM. A pronounced inhibition of cell 
viability using paclitaxel was achieved in combination 
with BI6727 indicating a synergistic action (combination 
index <1). Importantly, these observations were not cell-
type specific. Together, this set of experiments reveals a 
novel cooperation of PLK1 inhibition and microtubule-
targeting drugs like paclitaxel to reduce cell viability in 
ovarian cancer cell lines with CCNE1-amplification.
Paclitaxel and a PLK1 inhibitor cooperate to 
induce apoptosis in ovarian cancer cell lines with 
CCNE1-amplification
To examine the apoptotic response of cells arrested 
in the G2/M phase induced by a combinatorial treatment 
of paclitaxel and a PLK1 inhibitor, at first we treated 
OVCAR-3 cells with increasing doses of paclitaxel 
(2-4 nM) or 20 nM BI6727 and analyzed the induction 
of apoptosis by monitoring Caspase-3 cleavage as well 
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Figure 1: BI6727 treatment sensitizes ovarian cancer cells to paclitaxel. (A) OVCAR-3 cells were treated with increasing 
concentrations of BI6727 or (B) of paclitaxel (Pac). Cell viability was measured over 4 d using the Cell Titer-Blue® Cell Viability Assay. (C) 
(Left panel) The G2/M fraction was determined over 4 d post-treatment using flow cytometry. Measurements were statistically significant by 
two-tailed Student’s t-test (*P ≤ 0.05; **P ≤ 0.01). Each bar graph represents the mean value ± SEM (n=3). (Upper right panel) Endogenous 
levels of PLK1, Cyclin B1, phospho-Histone H3 and phospho-Aurora B were determined by immunoblotting. β-Actin served as loading 
control. (Lower right panel) The mitotic index was determined by measuring pH3(Ser10) levels. (D-G) OVCAR-3 cells were treated with 
either 20 nM BI6727 or increasing paclitaxel concentrations or both for 4 d. The cell viability was determined using the Cell Titer-Blue® 
Cell Viability Assay. Measurements were statistically significant by two-tailed Student’s t-test (*P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001). Each 
measurement represents the mean value ± SEM (n=3).
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as its downstream target, cleaved PARP, in western blot 
experiments (Figure 2A). While the cleavage of full-
length Caspase-3 and PARP, respectively, showed low to 
moderate levels at paclitaxel concentrations between 2 and 
4 nM for 24 h, the combinatorial treatment with 20 nM 
BI6727 induced strong cleavage of PARP and Caspase-3 
in particular at concentrations of 3.5 and 4 nM (Figure 
2A).
Moderate Caspase-3/7 activation could be detected 
after treatment of cells with paclitaxel alone (Figure 2B; 
2 nM activation to 1.6-fold, 2.5 nM activation to 1.8-fold, 
3 nM activation to 1.9-fold, 3.5 nM activation to 2.2-fold, 
4 nM activation to 2.7-fold). This activation could be 
enhanced by co-incubation with 20 nM BI6727 (20 nM 
BI6727 + 2 nM paclitaxel activation to 3.9-fold compared 
with 2 nM paclitaxel, P = 0.1, 20 nM BI6727 + 2.5 nM 
paclitaxel to 4.2-fold compared with 2.5 nM paclitaxel, 
P = 0.1, 20 nM BI6727 + 3.0 nM paclitaxel to 4-fold 
compared with 3 nM paclitaxel, P = 0.1, 20 nM BI6727 + 
4 nM paclitaxel to 5-fold compared with 4 nM paclitaxel, 
P = 0.1).
In addition, the cell cycle analysis by FACS 
revealed also a significant increase of the sub G0/G1 peak 
representing the apoptotic cell population comparing 
paclitaxel versus paclitaxel/BI6727-treated cells (Figure 
2C). We extended our evaluation to a genetic approach for 
PLK1 inhibition. The silencing of PLK1 was performed by 
using the most efficient PLK1-specific siRNA sequence 
obtained from “cherry picking” of the Dharmacon pool 
(Supplementary Figure 5A). PLK1 depletion by RNAi 
significantly increased paclitaxel-triggered apoptosis as 
documented by a significant increase of the sub G0/G1 
fraction (Supplementary Figure 5B, 5C).
Furthermore, cells were stained with PE Annexin 
V/7-AAD and analyzed using a flow cytometer (FACS). 
After incubation of OVCAR-3 cells with paclitaxel at 
concentrations between 2 and 4 nM for different time 
intervals we observed a small increase of Annexin 
V-positive cells: 24 h (2 nM paclitaxel 7%, 2.5 nM 7%, 
3 nM 8%, 3.5 nM 8%, 4 nM 9%), 48 h (2 nM paclitaxel 
8%; 2.5 nM 9%, 3 nM 11%; 3.5 nM 11%; 4 nM 14%) 72 
h (2 nM paclitaxel 8%; 2.5 nM 11%, 3 nM 15%; 3.5 nM 
16%; 4 nM 18%) and 96 h (2 nM paclitaxel 10%, 2.5 nM 
12%, 3 nM 18%, 3.5 nM 15%, 4 nM 32%), suggesting 
that up to 30% of the paclitaxel-treated cells had entered 
the apoptotic pathway versus 8% of apoptosis in control 
cells (Figure 2D). The co-incubation of cells with 20 
nM BI6727 and paclitaxel induced a more pronounced 
apoptosis up to 53% at a concentration of 4 nM paclitaxel: 
24 h (2 nM paclitaxel 15%, P < 0.01; 2.5 nM 19%, 3 nM 
18%; 3.5 nM 20%; 4 nM 18%), 48 h (2 nM paclitaxel 
25%; 2.5 nM 27%, 3 nM 28%; 3.5 nM 32%; 4 nM 31%) 
72 h (2 nM paclitaxel 36%; 2.5 nM 38%, 3 nM 39%; 3.5 
nM 42%; 4 nM 43%) and 96 h (2 nM paclitaxel 42%; 2.5 
nM 44%, 3 nM 37%; 3.5 nM 57%; 4 nM 53%). Together, 
this set of experiments shows that PLK1 inhibition and 
paclitaxel cooperate in a synergistic manner to induce 
apoptosis in ovarian cancer cell lines with CCNE1-
amplification based on our Annexin V experiments 
(combination index <1).
Combinatorial treatment with paclitaxel and the 
PLK1 inhibitor BI6727 induce mitochondrial 
apoptosis
Mitochondria play essential roles for the induction 
of apoptosis in mammalian cells. Members of the B-cell 
lymphoma 2 (BCL-2) family trigger the release of proteins 
from the space between the mitochondrial inner and 
outer membrane [43]. This process activates caspases 
that dismantle cells and signal efficient phagocytosis of 
cell corpses. The activation of either BCL-2- associated 
X protein (BAX) or BCL-2 antagonist or killer (BAK) 
is a key event for mitochondrial outer membrane 
permeabilization (MOMP) as cells lacking both proteins 
fail to undergo MOMP and apoptosis in response to 
apoptotic stimuli. First, we examined members of the 
anti-apoptotic BCL-2 family, which contribute to the 
regulation of the mitotic arrest [44]. Indeed, while 3.5 nM 
paclitaxel had no impact on the phosphorylation of BCL-
XL and of BCL-2, 20 nM BI6727 induced low levels of 
phosphorylation and the combinatorial treatment prompted 
elevated levels of both phosphorylation events (Figure 
3A, upper panels) associated with strong Caspase-3/7 
activity (Figure 3A, lower panel). The mitochondrial 
membrane potential (ΔΨm) is an important indicator of 
mitochondrial function and dysfunction. Using a flow 
cytometry method for the quantitative measurement of 
ΔΨm which utilizes the lipophilic, cationic, fluorescent 
probe 3,3′-dihexyloxacarbocyanine iodide (DiOC6(3)) we 
observed a significant loss of ΔΨm in the combinatorial 
treatment compared to the use of single agents (Figure 3B)
New studies have identified a pathway involving 
the protein Myeloid cell leukemia 1 (MCL-1), an anti-
apoptotic member of the BCL-2 family of apoptosis-
regulating proteins, that couples the timing of mitosis to 
the induction of apoptosis [44]. Pro-survival members, 
including MCL-1, inhibit apoptosis by blocking the cell 
death mediators BAX and BAK. When uninhibited, BAX 
and BAK permeabilize the outer mitochondrial membrane, 
which releases pro-apoptotic factors that activate caspases. 
During prolonged mitotic arrest, MCL-1 protein levels 
decline substantially, through polyubiquitination mediated 
by the tumor-suppressor protein FBW7, stimulating cell 
death. MCL-1 levels were not reduced in BI6727- or 
paclitaxel-treated cells (Figure 3C). PLK1 was recently 
shown to regulate the stability of FBW7 leading to the 
modulation of N-Myc levels [45]. We then sought to 
examine how PLK1 might affect FBW7 levels in ovarian 
cancer cells. Inhibition of PLK1 by BI6727 increased the 
protein abundance of FBW7 (Figure 3C). The addition of 
the 26S proteasome inhibitor, MG132, almost rescued the 
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Figure 2: The combinatorial treatment of BI6727 and paclitaxel induces pronounced levels of apoptosis. (A) OVCAR-3 
cells were treated with 20 nM BI6727, increasing paclitaxel concentrations or both. Apoptosis was analyzed 24 h post-treatment by western 
blotting for Caspase-3, full-length and cleaved PARP. β-Actin served as loading control. (B) Caspase-3/7-activity in whole cell lysates of 20 
nM BI6727, paclitaxel or both treated OVCAR-3 cells was measured 24 h and 48 h post-treatment using the Caspase-Glo® 3/7 Assay. Each 
bar graph represents the mean value ± SEM (n=2). Apoptosis was validated (C) by measuring the sub G0/G1 fractions or (D) by PE Annexin 
V staining. Measurements were statistically significant by two-tailed Student’s t-test (*P ≤ 0.05; **P ≤ 0.01). Each bar graph represents the 
mean value ± SEM (n=3).
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loss of MCL-1 caused by PLK1 inhibition, supporting the 
model that PLK1 regulates MCL-1 expression primarily 
via a posttranslational mechanism in OVCAR-3 cells 
(data not shown). The co-treatment including BI6727 
and paclitaxel caused the most pronounced stabilization 
of FBW7 compared to single treatments and led to a 
pronounced downregulation of the MCL-1 level (Figure 
3C). High levels of PLK1, Securin and phopho-H3 in co-
treated cells suggest that the inactivation of anti-apoptotic 
BCL-2 family members (downregulation of MCL-1, 
phosphorylation of BCL-XL and BCL-2) occurs in mitosis 
(Figure 3A). In summary, BI6727 and paclitaxel cooperate 
to activate the mitochondrial pathway leading to the 
activation of Caspase-3 (Figures 2A, 3A).
Figure 3: Analysis of apoptotic signaling in ovarian cancer cells. (A) (upper panel) Whole cell lysates of OVCAR-3 cells treated 
with BI6727 or 3.5 nM paclitaxel or both were analyzed evaluating marker proteins for mitochondrial-mediated apoptosis. Endogenous 
levels of PARP, cleaved PARP, Caspase-3, cleaved-Caspase-3, BCL-XL pS62, BCL-XL, pBCL-2, BAK, BAX, EndoG, Securin, PLK1, 
pHistone H3 and ß-Actin were determined by immunoblotting. Caspase-3/7-activity in whole cell lysates of 20 nM BI6727, paclitaxel or 
both treated OVCAR-3 cells was measured 48 h post-treatment using the Caspase-Glo® 3/7 Assay. (B) Evaluation of the mitochondrial 
membrane potential. The data are presented as means ± SD. Statistical analysis among treatment groups was performed. ** (P< 0.01), *** 
(P< 0.001). (C) Endogenous levels of FBW7, MCL-1, Cyclin E, Caspase-3 and ß-Actin were determined by immunoblotting using specific 
antibodies.
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Paclitaxel and PLK1 inhibition do not synergize 
to reduce cell viability in an ovarian cancer cell 
line without CCNE1-amplification
To study the effect of PLK1 inhibition and/or 
paclitaxel treatment on the viability of cells without
CCNE1-amplification, we tested Ovsaho cells 
(Supplementary Figure 1), which is a cell line showing 
the major genomic characteristics of HGSOC, and thus 
this cell line seems to be well suited as in vitro model 
for HGSOC [26]: This cell line has a TP53 mutation 
and its copy-number profile correlates well with the 
mean copy-number alterations of ovarian tumors. Its 
alteration pattern in the ovarian cancer-specific gene 
set matches TCGA samples. The IC50 was reached at 
concentrations >150 nM BI6727 in Ovsaho cells after 96 
h of treatment (Supplementary Figure 6A). The incubation 
with >10 nM paclitaxel for 72 h and 96 h reduced cell 
viability by more than 50% (Supplementary Figure 6B). 
Remarkably, the combinatorial treatment (24-72 h) of 
20-30 nM paclitaxel and 75 nM or 100 nM BI6727 did 
not induce a significant increase of Ovsaho cells in the 
G2/M phase (Supplementary Figure 6C). Furthermore, the 
combination of 75 nM or 100 nM BI6727 with increasing 
concentrations of paclitaxel (20-30 nM) for a period of 24 
h, 48 h and 72 h did not reduce the cell viability compared 
to single treatments (Supplementary Figure 6D-6F).
To examine the apoptotic response of Ovsaho cells 
induced by a combinatorial treatment of paclitaxel and a 
PLK1 inhibitor, we treated cells with increasing doses of 
paclitaxel (10-30 nM) or 100 nM BI6727 and analyzed 
the induction of apoptosis by monitoring cleaved PARP 
in western blot experiments (Supplementary Figure 
7A). While low levels of PARP cleavage were visible at 
paclitaxel concentrations between 10-30 nM at 72 h, the 
combinatorial treatment with 100 nM BI6727 induced a 
small increase of PARP cleavage (Supplementary Figure 
7A). In line with these observations, the cell cycle analysis 
by FACS did not show a significant increase of the sub 
G0/G1 peak representing the apoptotic cell population 
comparing paclitaxel versus paclitaxel/BI6727-treated 
cells (Supplementary Figure 7B). Furthermore, cells were 
stained with PE Annexin V or PE Annexin V/7-AAD and 
analyzed using a flow cytometer (FACS) (Supplementary 
Figure 7C, 7D). Both measurements did not provide 
evidence for a significant increase of apoptosis under the 
combinatorial treatment compared to single treatments 
showing a remarkable difference to both ovarian cancer cell 
lines with CCNE1-amplification (OVCAR-3, COV318).
The impact of combined treatment with PLK1 
inhibitor and paclitaxel on the clonogenic 
survival of ovarian cancer cells
To study the tumorigenic potential of cells treated 
with BI6727 and paclitaxel, we tested for the ability of 
cells to survive and to form colonies. Briefly, for this 
colony formation assay, cells were cultured for 24 h in 
the presence of 20 nM BI6727 or 3.5 nM paclitaxel or 
20 nM BI6727/3.5 nM paclitaxel and then re-plated in 
6 well-plates (2000 cells/well) in inhibitor-free medium 
(Figure 4A). After 9 d the resulting colonies were stained 
with Coomassie blue and phenotypically inspected using a 
phase-contrast microscope (Figure 4B). The results of the 
long-term experiments revealed that BI6727 and paclitaxel 
acted together to significantly reduce the colony forming 
ability (20 nM BI6727 121 colonies; 3.5 nM paclitaxel 103 
colonies; 3.5 nM paclitaxel/20 nM BI6727 41 colonies, 
P < 0.01) (Figure 4C) and to synergistically reduce cell 
viability in a three-dimensional (3-D) multicellular model 
(20 nM BI6727 123%; 2.5 nM paclitaxel 84%; 2.5 nM 
paclitaxel/20 nM BI6727 212%, P < 0.01) (Figure 4D), 
which are widely used as avascular tumor model for 
metastasis and invasion research.
PLK1 inhibitor and paclitaxel synergistically 
induce apoptosis and suppress clonogenic growth 
in primary, patient-derived ovarian cancer cell 
cultures
To evaluate the physiological relevance of our 
observations, we extended our study to a primary ovarian 
cancer cell culture established from tumor specimen 
derived from patients diagnosed with HGSOC. The 
incubation with BI6727 at concentrations between 5 
and 100 nM for 24 h increased the fraction of HGSOC 
cells in the G2/M phase from 14% to 42% (Figure 5A). 
Notably, paclitaxel and BI6727 synergized to reduce cell 
growth in short-term (72 h) (3.125 nM paclitaxel 86%; 
3.125 nM paclitaxel/100 nM BI6727 61%) and long-
term (5 nM paclitaxel 95%; 100 nM BI6727 120%; 5 nM 
paclitaxel/100 nM BI6727 75%, P < 0.05) experiments (6 
days) (Figure 5B, 5C). The analysis of the 3-D cultures 
revealed a significant increase of dead cells by the 
combinatorial treatment compared to single agents (Figure 
5D). The co-treatment with paclitaxel and BI6727 reduced 
both cell viability and 3-D colony formation in the primary 
ovarian culture (Figure 5B-5D). Furthermore, we analyzed 
a sample derived from a second patient diagnosed with 
HGSOC (Supplementary Figure 8). The co-treatment with 
paclitaxel and BI6727 confirmed the significant reduction 
of cell viability and 3-D colony formation (Supplementary 
Figure 8A-8C) supporting the clinical relevance of this 
combinatorial approach in the primary ovarian culture.
The inhibition of PLK1 supports a reduction of 
the paclitaxel-induced neurotoxicity
As paclitaxel is known to harm neuronal cells 
in patients, we investigated whether a combinatorial 
treatment with paclitaxel and BI6727 might reduce 
neuronal toxicity. To address this aspect, we used the 
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Nerve Growth Factor (NGF)-induced neurite outgrowth 
assay in the rat pheochromocytoma cell line PC-12, 
which is an established in vitro model and is often used 
to study neuronal differentiation and neurotoxicity [46] 
(Figure 6A). A significant reduction of the number of 
cells expressing neurites was determined with 5 nM and 
10 nM paclitaxel to 78% and 62%, respectively (P<0.05). 
Subsequently, we compared the neurotoxic effect of 
different drugs at their IC50 in OVCAR-3 cells: 10 nM 
paclitaxel vs. 3.5 nM paclitaxel and 20 nM BI6727. The 
co-incubation of 3.5 nM paclitaxel and 20 nM BI6727 
showed a positive effect, increasing the percentage of 
neurite-forming cells from 62% (10 nM paclitaxel) to 
101% (3.5 nM paclitaxel/ 20 nM BI6727) (P<0.05) 
(Figure 6B). Furthermore, we also observed a positive 
effect on the length of processes 12.63 nm vs. 14.72 nm 
comparing 10 nM paclitaxel vs. 3.5 nM paclitaxel/20 nM 
BI6727 (Figure 6C). Thus, the reduction of the paclitaxel 
concentration made possible by the addition of BI6727 
reduces the neurotoxicity in the PC-12-based model 
system.
DISCUSSION
Paclitaxel is a front-line drug for ovarian cancer 
chemotherapy, along with the platinum agents. Defining 
Figure 4: Combinatorial treatment of OVCAR-3 cells with 20 nM BI6727 and 3. 5 nM paclitaxel displays long lasting 
inhibition of cell growth. (A) Experimental set up of long-term analyzes. (B) Coomassie stained regrown colonies of OVCAR-3 cells 
treated with 20 nM BI6727, 3.5 nM paclitaxel or both for 24 h. (C) The number of colonies was determined. Numbers were statistically 
significant by two-tailed Student’s t-test (*P≤ 0.05; **P≤ 0.01). Each bar graph represents the mean value ± SEM (n=3). (D) OVCAR-3 cells 
were grown as 3-D culture over 14 d and treated with 20 nM BI6727, 2.5 nM paclitaxel or both for 5 d. Cells were stained using the LIVE/
DEAD viability/cytotoxicity kit and ratios of viable/dead cells were calculated. Measurements were statistically significant by two-tailed 
Student’s t-test (*P≤ 0.05; **P≤ 0.01). Each bar graph represents the mean value ± SEM (n=3).
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Figure 5: BI6727 treatment sensitizes patient-derived HGSOC cells to paclitaxel. (A) Primary tumor cells were treated with 
increasing BI6727 concentrations and the cell cycle distribution was analyzed by flow cytometry. (B) Primary tumor cells were either 
treated with increasing paclitaxel concentrations or both (increasing concentrations of paclitaxel and 100 nM BI6727). The cell viability 
was determined for 72 h or (C) over a period of 6 d using the Cell Titer-Blue Cell® Viability Assay. (D) 3-D cultures grown out of primary 
tumor cells were treated with either 5 nM paclitaxel, 50 nM BI6727 or both for 7 d. Cells were stained and fluorescence intensities of dead 
cells were determined. Measurements were statistically significant by two-tailed Student’s t-test (*P≤ 0.05; **P≤ 0.01). Each bar graph 
represents the mean value ± SEM (n=3).
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the appropriate dosage schedule for paclitaxel in chemo-
naïve and recurrent ovarian cancer and elucidating the 
mechanisms of taxane resistance are areas of intense 
research. Importantly, avoiding troublesome / irreversible 
adverse effects and improving clinical efficacy are of 
utmost interest for the therapy of HGSOC. Peripheral 
neurotoxicity is the major non-hematological adverse 
effect of taxane, which is often painful and sometimes 
irreversible. In view of unwanted side-effects associated 
with conventional chemotherapy, decreasing the dose 
of paclitaxel is a valuable strategy to limit neurotoxicity 
and to improve the clinical efficacy in combinatorial 
treatments. In this study, we utilized a human siRNA 
library targeting 711 kinases for the screening of ovarian 
cancer cells with CCNE1-amplification as a model to 
identify protein kinase targets suitable for new synthetic 
lethal drug interactions that could optimize the paclitaxel-
mediated therapeutic effects. We identified a novel 
combinatorial approach of paclitaxel and the small 
molecule inhibitor of PLK1, BI6727, to induce growth 
inhibition and apoptosis in ovarian cancer cell lines with 
CCNE1-amplification. The calculation of combination 
indexes suggests synergistic lethality, which indicates 
the potency of this drug combination. Importantly, the 
examination of primary ovarian cancer cells revealed 
cooperative anti-tumor cell activity of BI6727 and 
paclitaxel causing synergistic apoptosis and emphasizing 
the clinical relevance of our investigation. In contrast, 
the combinatorial treatment of an ovarian cancer cell line 
without CCNE1-amplification with paclitaxel and BI6727 
did not provide evidence for synthetic lethality.
Mitochondrial outer membrane permeabilization 
(MOMP) is often essential for the activation of the 
caspase proteases that are responsible for apoptotic cell 
Figure 6: The combinatorial treatment of paclitaxel and BI6727 reduces neurotoxicity. (A) Experimental set up of neurotoxicity 
analysis using PC-12 cells. (B) PC-12 cells were differentiated into neurons using β-NGF. The outgrowth of neurites was analyzed 24 h and 
48 h post-treatment and cells displaying elongations were counted. Numbers were statistically significant by two-tailed Student’s t-test (*P≤ 
0.05). Each bar graph represents the mean value ± SEM (n=3). (C) The lengths of neurites were measured 24 h/48 h post-treatment and 
depicted as Scatter plots. Measurements were statistically significant by Student’s t-test (*P≤ 0.05; **P≤ 0.01; ***P≤ 0.001).
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death. Various intermembrane space (IMS) proteins 
are released. Following MOMP by pro-apoptotic BAX 
or BAK, additional regulatory mechanisms govern 
the mitochondrial release of IMS proteins and caspase 
activity. MOMP typically leads to cell death irrespective 
of caspase activity by causing a progressive decline in 
mitochondrial function. In our study, we have tried to 
further our knowledge on the mechanisms that contribute 
to an induction of apoptosis upon BI6727/paclitaxel 
treatment, which induces a pronounced mitotic arrest and 
cell death. BI6727 and paclitaxel cooperate to disable anti-
apoptotic BCL-2 family proteins by inactivating BCL-2 
and BCL-XL via phosphorylation and by downregulating 
MCL-1 shifting the balance between pro- and anti-
apoptotic BCL-2 family proteins toward apoptosis. 
In concordance with our data, it has been shown that 
upon mitotic arrest the phosphorylation and subsequent 
ubiquitination of MCL-1 lead to its degradation [37, 44, 
47]. Moreover, it could be demonstrated that phospho-
defective BCL-2 and BCL-XL mutants block mitotic cell 
death compared to the corresponding wild-type proteins 
and the phosphorylation of BCL-XL reduces its capacity 
to antagonize pro-apoptotic BAX [48–50].
Given our current knowledge on the regulation of 
apoptosis during prolonged mitotic arrest induced by 
microtubule-targeting drugs two strategies to increase the 
efficacy of spindle-poisons like paclitaxel are 1) extending 
the duration of the mitotic arrest and 2) accelerating the 
degradation of the apoptotic timer. In other words, in 
order to shift the balance from cell survival to apoptosis, 
the rate of Cyclin B1 degradation needs to be slowed 
and the rate of MCL-1 degradation must be increased. 
Various signaling pathways are involved in the regulation 
of MCL-1 stability: When MCL-1 expression is increased 
following mitotic arrest, its degradation is controlled by 
different regulators [44]. FBW7, the substrate-binding 
component of a ubiquitin ligase complex, targets MCL-
1 for degradation by the 26S proteasome, whereas the 
deubiquitinase USP9X reverses the polyubiquitinating 
activity of the FBW7 complex [51]. During mitotic 
arrest, the activities of Jun N-terminal kinase (JNK), 
the mitogen-activated protein kinase (MAPK) family 
member p38, and casein kinase II (CKII) are upregulated, 
increasing the phosphorylation of MCL-1, interaction 
with FBW7, and the subsequent polyubiquitination of 
MCL-1, which leads to degradation via the proteasome 
and continually decreasing concentrations of MCL-1 
during mitotic arrest [52]. A recent study revealed that 
PLK1 reduces FBW7 stability through promotion of its 
phosphorylation and autopolyubiquitination [45]. To 
evaluate the role of PLK1 for the stability of FBW7 in 
ovarian cancer cells, we tested BI6727 for its capacity 
to trigger the level of FBW7. PLK1 inhibition increased 
the protein level of endogenous FBW7. Thus, the 
combinatorial treatment with BI6727 and paclitaxel had 
a strong impact to increase the endogenous level of the 
tumor suppressor FBW7.
Although point mutations are rare in ovarian tumors, 
a hallmark of this cancer type is the mutation of the tumor 
suppressor P53 with over 94% in HGSOC [53], which 
could correlate with a loss of the tumor suppression 
function of P53, including cell cycle inhibition, apoptosis, 
senescence, DNA repair and autophagy, as well as 
processes that oppose oncogenic metabolic reprogramming 
[54]. The mutation of P53 which results in loss of these 
tumor suppressive functions, increases transcript and 
protein levels of Aurora A and PLK1 [55] making PLK1 
an attractive target for cancers with TP53 mutation like 
HGSOC. By analyses of ‘The Cancer Genome Atlas’ 
datasets, PLK1 expression levels were found to be 
significantly higher in P53-mutated than in P53–wild-
type cancers [56], which also correlates to the observation 
that the FoxM1 transcription factor network that regulates 
PLK1 expression was found to be upregulated in 87% of 
patients with HGSOC [57]. FBW7 expression was found 
to be negatively correlated with the malignant potential 
of ovarian tumors [58]. That is to say, FBW7 expression 
levels in ovarian cancer samples were significantly lower 
than those in borderline and benign tumors (P < 0.01). 
This study suggests that TP53 mutations might suppress 
FBW7 expression through DNA hypermethylation of 
FBW7 5'-upstream regions. Thus, FBW7 expression was 
found to be downregulated in ovarian cancers and was 
associated with P53 mutations and the DNA methylation 
status of the 5'-upstream regions of FBW7. By means of 
inhibiting the catalytic activity of PLK1, we were able 
to stabilize the endogenous level of FBW7, which was 
associated in combinatorial experiments with a strong 
downregulation of the critical mitotic timer MCL-1 and 
the oncogenic driver Cyclin E (Supplementary Figure 9). 
Consequently, we could enhance the sensitivity of HGSOC 
to paclitaxel by inhibiting PLK1 activity. In an ovarian 
cancer cell line without CCNE1-amplification, Ovsaho 
cells, a synergy of BI6727- and paclitaxel-treatment was 
not observed which might suggest that the preservation 
of endogenous FBW7 levels leading to downregulation of 
endogenous Cyclin E is an attractive strategy to sensitize 
ovarian cancer cells with CCNE1-amplification. To date, 
there have been no clinical trials in which patients were 
selected based on CCNE1-amplification status, and 
unfortunately, there are no currently available drugs which 
specifically target Cyclin E1. Hence, several alternative 
approaches have been proposed to decrease the viability 
of the CCNE1-amplified subset of cancer cells, including 
the use of several CDK inhibitors [59] and the proteasome 
inhibitor Bortezomib [27]. Thus, targeting Cyclin E1 by a 
PLK1 inhibition-based stabilization of FBW7 might be a 
novel approach to increase apoptosis in CCNE1-amplified 
ovarian cancer cells.
PLK1 holds great promise as therapeutic target. 
Promising results for the treatment of cultured cancer 
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cells and preclinical trials were reported for Volasertib 
monotherapy [60]. Volasertib (BI6727) is under current 
investigation in multiple ongoing clinical trials [61, 
62]. However, various lines of evidence from clinical 
trials revealed that Volasertib alone shows different 
degrees of efficacy, and only a fraction of patients 
responds well to single-agent Volasertib suggesting that 
better patient stratifications and optimized treatment 
regimens are urgently needed. Here, we have identified 
a pharmacological interaction between Volasertib 
and paclitaxel, arguing that prolonging mitotic arrest 
associated with a stimulation of pro-apoptotic pathways 
and a downregulation of the oncogenic driver Cyclin E 
may serve as a useful strategy in ovarian cancer cells with 
CCNE1-amplification.
MATERIALS AND METHODS
Experimental details on patient samples, genomic 
profiling, high throughput siRNA transfection, antibodies 
and chemicals, western blot analysis, colony formation 
assays and neurite outgrowth assays are given in 
Supplementary Information.
Cell culture
The ovarian carcinoma cell lines OVCAR-3 Ovsaho 
were cultured in RPMI 1640 (Gibco) and COV318 in 
DMEM (Gibco), respectively, both containing 10% FCS 
(Gibco) and 1% Penicillin/Streptomycin (Sigma-Aldrich). 
COV318 cells needed additional 2 mM glutamate (Sigma-
Aldrich). PC-12 cells were cultured in DMEM GlutaMAX 
(Gibco) supplied with 10% FCS, 5% horse serum (Gibco) 
and 1% Penicillin/Streptomycin.
Primary cells were isolated from HGSOC using 
the tumor dissociation kit (Max Miltenyi 130-095-929) 
together with the tumor cell isolation kit (Max Miltenyi 
130-108-339) following the manufacturer’s instructions. 
Isolated cells were cultured as described [63] and 
subsequently adapted to normal cell culture medium 
containing 10% FCS without growth supplements.
3-D cultures
A cell suspension of 3000 cells/ 50 ul was prepared 
and pipetted from the topside into a 96 well Perfect 3D 
Hanging Drop plate (BioTrend). Plates were incubated at 
37°C for several days until hanging drops have developed. 
The 3-D culture was harvested on a 96 well plate covered 
with 1% agarose by low spin centrifugation. Treatment 
of cells with BI6727 and paclitaxel was performed as 
indicated for 7 to 14 days. Cells were stained with the 
LIVE/DEAD viability/ cytotoxicity kit (Molecular 
Probes/Thermofisher) for 30 min and inspected using a 
fluorescence microscope. The polyanionic dye calcein is 
retained in live cells, producing an intense uniform green 
fluorescence, while EthD-1 enters cells with damaged 
membranes thereby producing a bright red fluorescence 
upon binding to nucleic acids in dead cells. The ratio of 
viable/dead cells were calculated with the software ImageJ 
Fiji.
Cell proliferation and Caspase-3/7-activity 
(multiplexed protocol)
48 h following transfection 7 μl substrate of the 
Cell Titer-Blue® Cell Viability Assay (Promega) were 
added to each well. After a short centrifugation step 
(1,000 rpm for 10 sec) cells were incubated for further 3 
h at 37°C / 5% CO2 before fluorescence reading (Victor 
X4, PerkinElmer). The activity of Caspase-3/7 was 
determined using the Caspase-Glo® 3/7 Assay (Promega). 
20 μl substrate per well were applied and after 30 minutes 
shaking at room temperature in the dark, luminescence 
was detected (Victor X4, Perkin Elmer). The analysis of 
data was partially done online by Networkanalyst and 
GraphPad Prism.
Cell cycle and apoptosis assays
Paclitaxel and/or BI6727 treatment was conducted 
at least overnight followed by cell cycle and apoptosis 
measurements after predefined time intervals. For cell 
cycle analysis, cells were harvested, washed, fixed with 
70% EtOH and stained as described [10]. Cell cycle 
quantification was performed using a FACS Calibur 
and Cellquest Pro software (both BD Biosciences). The 
activity of Caspase-3/7 was determined in cell lysates 
using the Caspase-Glo®3/7 Assay according to the 
manufacturer's instructions. Apoptotic loss of membrane 
asymmetry was analyzed by staining for OVCAR-3 cells 
(BD Biosciences) on a FACS Calibur.
Proliferation assays
To measure cell proliferation using the Cell Titer-
Blue® Cell Viability Assay, 2500 cells per well were 
seeded in 96-well plates and treated with paclitaxel, 
BI6727 or both. Cells were incubated with 20 μl substrate 
of the Cell Titer-Blue® Cell Viability Assay for 4 h and 
the light absorbance was measured at 540 nm (Victor X4, 
Perkin Elmer). The 50% growth inhibitory concentration 
(GI 50) was estimated using the following formula: 100 x 
(T – T0)/(C – T0) = 50, where T is the optical density (OD) 
value after drug treatment, T0 is the OD value at time 0, 
and C is the OD value for the diluent treatment [64]. Time 
0 was defined as the day the drug was administered.
Statistical analysis
All experiments were performed at least three times 
and displayed as mean and standard error of the mean. 
The statistical significance was assessed by Student’s t-test 
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(two-tailed and paired) using Excel 2010 (Microsoft) as 
well as GraphPad Prism 7 (GraphPad, La Jolla, CA, USA). 
Significant differences (*P≤0.05; **P≤0.01; ***P≤0.001) are 
indicated in the figures with asterisks.
Image work
Images were opened in Adobe Photoshop CS6, sized 
and placed in figures using Adobe Illustrator CS6 (Adobe 
Systems, Mountain View, CA).
Abbreviations
CI- combination index, FACS- flow cytometry, 
FCS- fetal bovine serum, GI- growth inhibition, HGSOC- 
high grade serous ovarian carcinoma, IC- inhibitory 
concentration, Pac- paclitaxel, pH3- phospho-histone H3, 
PLK1- Polo-like kinase, siRNA- small interfering RNA, 
SCF- complex of SKP1, CUL1 and F-box protein.
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